A System out of Breath: How Hypoxia Possibly Contributes to the Pathogenesis of Systemic Sclerosis

Overview

Journal Int J Rheumatol

Publisher Wiley

Specialty Rheumatology

Date 2011 Dec 14

PMID 22162692

Citations 9

Authors

T W van Hal

L van Bon

T R D J Radstake

Affiliations

Soon will be listed here.

Abstract

Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular alterations and immunological disturbances and fibrosis, the order of which remains to be fully determined. Clinically, patients show clear signs of hypoxia in skin and internal organs. The low oxygen tension is potentially caused by a yet to be indentified circuitry involving the three features that typify SSc. In addition, once present, the hypoxia creates a vicious circle of ongoing pathology. In this paper, we provide an overview of the evidence that points towards the mechanisms causing hypoxia in SSc. In addition, data that suggest how hypoxia itself may orchestrate worsening of symptoms is presented. Altogether, it is clear that hypoxia is an important hallmark in SSc patients. By providing an overview of the mechanisms at play and the possible therapeutic avenues that have emerged, we hope to stimulate researchers to provide novel clues into the conundrum in SSc patients.

Citing Articles

Carbon Monoxide Poisoning: From Occupational Health to Emergency Medicine.

Savioli G, Gri N, Ceresa I, Piccioni A, Zanza C, Longhitano Y J Clin Med. 2024; 13(9).

PMID: 38730995 PMC: 11084260. DOI: 10.3390/jcm13092466.

Nuclear Receptor Subfamily 4A Signaling as a Key Disease Pathway of CD1c+ Dendritic Cell Dysregulation in Systemic Sclerosis.

Servaas N, Hiddingh S, Chouri E, Wichers C, Affandi A, Ottria A Arthritis Rheumatol. 2022; 75(2):279-292.

PMID: 36482877 PMC: 10108054. DOI: 10.1002/art.42319.

Hypoxia-induced interstitial transformation of microvascular endothelial cells by mediating HIF-1α/VEGF signaling in systemic sclerosis.

Mao J, Liu J, Zhou M, Wang G, Xiong X, Deng Y PLoS One. 2022; 17(3):e0263369.

PMID: 35231032 PMC: 8887755. DOI: 10.1371/journal.pone.0263369.

Autoimmune Connective Tissue Disease Following Carbon Monoxide Poisoning: A Nationwide Population-Based Cohort Study.

Huang C, Ho C, Chen Y, Hsu C, Lin H, Wang J Clin Epidemiol. 2020; 12:1287-1298.

PMID: 33262659 PMC: 7686473. DOI: 10.2147/CLEP.S266396.

State-of-the-art technologies provide new insights linking skin and blood vessel abnormalities in SSc-related disorders.

Dinsdale G, Wilkinson S, Wilkinson J, Moore T, Manning J, Berks M Microvasc Res. 2020; 130:104006.

PMID: 32320708 PMC: 7522709. DOI: 10.1016/j.mvr.2020.104006.

References

Avouac J, Juin F, Wipff J, Couraud P, Chiocchia G, Kahan A . Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis. 2008; 67(10):1455-60. DOI: 10.1136/ard.2007.082131. View

Roberts D, Kearney J, Johnson J, Rosenberg M, Kumar R, Bautch V . The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol. 2004; 164(5):1531-5. PMC: 1615669. DOI: 10.1016/S0002-9440(10)63711-X. View

Ratcliffe P . HIF-1 and HIF-2: working alone or together in hypoxia?. J Clin Invest. 2007; 117(4):862-5. PMC: 1838952. DOI: 10.1172/JCI31750. View

Ivan M, Haberberger T, Gervasi D, Michelson K, Gunzler V, Kondo K . Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A. 2002; 99(21):13459-64. PMC: 129695. DOI: 10.1073/pnas.192342099. View

Cramer T, Yamanishi Y, Clausen B, Forster I, Pawlinski R, Mackman N . HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 2003; 112(5):645-57. PMC: 4480774. DOI: 10.1016/s0092-8674(03)00154-5. View

Holt C, Lindsey N, Moult J, Malia R, Greaves M, Hume A . Antibody-dependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis. Clin Exp Immunol. 1989; 78(3):359-65. PMC: 1534812. View

Higgins D, Biju M, Akai Y, Wutz A, Johnson R, Haase V . Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol. 2004; 287(6):F1223-32. DOI: 10.1152/ajprenal.00245.2004. View

Zhou G, Dada L, Wu M, Kelly A, Trejo H, Zhou Q . Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1. Am J Physiol Lung Cell Mol Physiol. 2009; 297(6):L1120-30. PMC: 2793183. DOI: 10.1152/ajplung.00007.2009. View

Higgins D, Kimura K, Bernhardt W, Shrimanker N, Akai Y, Hohenstein B . Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest. 2007; 117(12):3810-20. PMC: 2082142. DOI: 10.1172/JCI30487. View

10.

Beyer C, Schett G, Gay S, Distler O, Distler J . Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther. 2009; 11(2):220. PMC: 2688169. DOI: 10.1186/ar2598. View

11.

Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y . Defective vasculogenesis in systemic sclerosis. Lancet. 2004; 364(9434):603-10. DOI: 10.1016/S0140-6736(04)16853-0. View

12.

Spirig R, Djafarzadeh S, Regueira T, Shaw S, von Garnier C, Takala J . Effects of TLR agonists on the hypoxia-regulated transcription factor HIF-1alpha and dendritic cell maturation under normoxic conditions. PLoS One. 2010; 5(6):e0010983. PMC: 2881864. DOI: 10.1371/journal.pone.0010983. View

13.

Distler J, Jungel A, Pileckyte M, Zwerina J, Michel B, Gay R . Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum. 2007; 56(12):4203-15. DOI: 10.1002/art.23074. View

14.

Brahimi-Horn M, Pouyssegur J . HIF at a glance. J Cell Sci. 2009; 122(Pt 8):1055-7. DOI: 10.1242/jcs.035022. View

15.

Giovannetti A, Rosato E, Renzi C, Maselli A, Gambardella L, Giammarioli A . Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes. Clin Immunol. 2010; 137(1):122-33. DOI: 10.1016/j.clim.2010.06.004. View

16.

Gay S, Jones Jr R, Huang G, Gay R . Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol. 1989; 92(2):301-3. DOI: 10.1111/1523-1747.ep12276895. View

17.

Distler O, Rosso A, Giacomelli R, Cipriani P, Conforti M, Guiducci S . Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 2002; 4(6):R11. PMC: 153841. DOI: 10.1186/ar596. View

18.

Silverstein J, Steen V, Medsger Jr T, Falanga V . Cutaneous hypoxia in patients with systemic sclerosis (scleroderma). Arch Dermatol. 1988; 124(9):1379-82. View

19.

Avouac J, Wipff J, Goldman O, Ruiz B, Couraud P, Chiocchia G . Angiogenesis in systemic sclerosis: impaired expression of vascular endothelial growth factor receptor 1 in endothelial progenitor-derived cells under hypoxic conditions. Arthritis Rheum. 2008; 58(11):3550-61. DOI: 10.1002/art.23968. View

20.

Papa N, Colombo G, Fracchiolla N, Moronetti L, Ingegnoli F, Maglione W . Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum. 2004; 50(4):1296-304. DOI: 10.1002/art.20116. View